 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 July 2001 | Volume 135 Issue 1 | Pages 17-26
Background: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active anti-retroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment.
Objective: To assess the benefit of HAART in patients with advanced AIDS and anemia.
Design: Prospective, multicenter cohort study.
Setting: The Viral Activation Transfusion Study (VATS), with enrollment from August 1995 through July 1998 and follow-up through June 1999.
Patients: 528 HIV-infected patients with cytomegalovirus (CMV) seropositivity or disease who were receiving a first red blood cell transfusion for anemia.
Measurements: In a person-year analysis of follow-up before and after initiation of HAART, Poisson regression was used to calculate crude rate ratios and rate ratios adjusted for CD4 count, HIV RNA level, calendar period, time on study, sex, ethnicity, and injection drug use.
Results: At baseline, patients had a median CD4+ lymphocyte count of 0.015 x 109 cell/L, median plasma HIV RNA level of 4.8 log10 copies/mL, and median hemoglobin concentration of 73 g/L. Use of HAART increased from 1% of active patients in January 1996 to 79% of active patients in January 1999. The crude death rate was 0.24 event/person-year among patients taking HAART and 0.88 event/person-year among those not taking HAART (rate ratio, 0.26; adjusted rate ratio, 0.38; P < 0.001 for both comparisons). Rates of non-CMV disease were 0.15 event/person-year after HAART and 0.45 event/person-year before HAART (crude rate ratio, 0.34 [P < 0.001]; adjusted rate ratio, 0.66 [P < 0.05]). Rates of CMV disease were 0.10 event/person-year after HAART and 0.25 before HAART (crude rate ratio, 0.42 [P < 0.01]; adjusted rate ratio, 1.01 [P > 0.2]). Results were similar in patients with baseline CD4+ lymphocyte counts less than 0.010 x 109 cells/L.
Conclusions: The data support an independent reduction in mortality and opportunistic events attributable to HAART, even in patients with very advanced HIV disease. However, patients with CMV infection or disease may not have a reduction in new CMV events due to HAART.
*For a list of the Viral Activation Transfusion Study Investigators, see Appendix.
Author and Article Information
From University of California, San Francisco, San Francisco, California; University of Washington, Seattle, Washington; New England Research Institutes, Watertown, Massachusetts; Ohio State University, Columbus, Ohio; Miriam Hospital, Brown University, Providence, Rhode Island; Georgetown University, Washington, D.C.; Mount Sinai Medical Center, New York, New York; and National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Acknowledgments: The authors thank the patients and the transfusion service and hospital nursing personnel.
Grant Support: By National Heart, Lung, and Blood Institute contract N01-HB-57121.
Requests for Single Reprints: Edward L. Murphy, MD, MPH, Department of Laboratory Medicine, University of California, San Francisco, Box 0884, San Francisco, CA 94143-0884; e-mail, murphy{at}itsa.ucsf.edu.
Current Author Addresses: Dr. Murphy: Department of Laboratory Medicine, University of California, San Francisco, Box 0884, San Francisco, CA 94143-0884
Dr. Collier: University of Washington, Box 359929, 325 9th Avenue, Seattle, WA 98104.
Dr. Kalish and Assmann: New England Research Institute, 9 Galen Street, Watertown, MA 02472.
Dr. Para: Ohio State University, 456 West 10th Avenue, Columbus, OH 43210.
Dr. Flanigan: Brown University Medical School, Miriam Hospital, 164 Summit Avenue, Providence, RI 02906-2853.
Dr. Kumar: Georgetown University Medical Center, 3800 Reservoir Road, Washington, DC 20007.
Ms. Mintz and Dr. Wallach: Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029.
Dr. Nemo: National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892.
Author Contributions: Conception and design: E.L. Murphy, A.C. Collier, L.A. Kalish, S.F. Assmann, M.F. Para, T.P. Flanigan, P.N. Kumar.
Analysis and interpretation of the data: E.L. Murphy, A.C. Collier, L.A. Kalish, S.F. Assmann, P.N. Kumar.
Drafting of the article: E.L. Murphy, S.F. Assmann, P.N. Kumar.
Critical revision of the article for important intellectual content: E.L. Murphy, A.C. Collier, L.A. Kalish, S.F. Assmann, M.F. Para, T.P. Flanigan, P.N. Kumar.
Final approval of the article: E.L. Murphy, A.C. Collier, L.A. Kalish, S.F. Assmann, M.F. Para, T.P. Flanigan, P.N. Kumar, G.J. Nemo.
Provision of study materials or patients: A.C. Collier, M.F. Para, P.N. Kumar, L. Mintz, F.R. Wallach.
Statistical expertise: L.A. Kalish, S.F. Assmann.
Obtaining of funding: A.C. Collier, L.A. Kalish, G.J. Nemo.
Administrative, technical, or logistic support: A.C. Collier, F.R. Wallach, G.J. Nemo.
Collection and assembly of data: E.L. Murphy, A.C. Collier, T.P. Flanigan, P.N. Kumar, L. Mintz. ARTICLE
Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  K. Covens, N. Dekeersmaeker, Y. Schrooten, J. Weber, D. Schols, M. E. Quinones-Mateu, A.-M. Vandamme, and K. Van Laethem Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs J. Clin. Microbiol., July 1, 2009; 47(7): 2232 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aoki, D. J. Venzon, Y. Koh, H. Aoki-Ogata, T. Miyakawa, K. Yoshimura, K. Maeda, and H. Mitsuya Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors J. Virol., April 1, 2009; 83(7): 3059 - 3068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Lyons, C. J Lindsell, D. L Raab, A. H Ruffner, A. T Trott, and C. J Fichtenbaum Comparison of emergency department HIV testing data with visit or patient as the unit of analysis J Med Screen, March 1, 2009; 16(1): 29 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Koh, D. Das, S. Leschenko, H. Nakata, H. Ogata-Aoki, M. Amano, M. Nakayama, A. K. Ghosh, and H. Mitsuya GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro Antimicrob. Agents Chemother., March 1, 2009; 53(3): 997 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Bedimo Body-Fat Abnormalities in Patients With HIV: Progress and Challenges J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2008; 7(6): 292 - 305. [Abstract] [PDF]
|
|
|
|
|
|
C. Paar, C. Palmetshofer, K. Flieger, M. Geit, R. Kaiser, H. Stekel, and J. Berg Genotypic Antiretroviral Resistance Testing for Human Immunodeficiency Virus Type 1 Integrase Inhibitors by Use of the TruGene Sequencing System J. Clin. Microbiol., December 1, 2008; 46(12): 4087 - 4090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M Kitahata, B. Rodriguez, R. Haubrich, S. Boswell, W C. Mathews, M. M Lederman, W. B Lober, S. E Van Rompaey, H. M Crane, R. D Moore, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems Int. J. Epidemiol., October 1, 2008; 37(5): 948 - 955. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Yoon, D. Chawla, T. Paal, M. Ndungu, Y. Du, S. Kurtkaya, A. Sun, J. P. Snyder, and R. K. Plemper High-Throughput Screening--Based Identification of Paramyxovirus Inhibitors J Biomol Screen, August 1, 2008; 13(7): 591 - 608. [Abstract] [PDF]
|
|
|
|
 |
|
 C M Wilcox and M S Saag Gastrointestinal complications of HIV infection: changing priorities in the HAART era Gut, June 1, 2008; 57(6): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rodriguez, H. Valdez, A. Mijch, K. Watson, M. M. Lederman, G. A. McComsey, C. V. Loupa, and I. Woolley Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2007; 6(3): 198 - 202. [Abstract] [PDF]
|
|
|
|
|
|
L. K. White, J.-J. Yoon, J. K. Lee, A. Sun, Y. Du, H. Fu, J. P. Snyder, and R. K. Plemper Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2293 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gilden, J. M. Kubisiak, and D. M. Gilden Managing Medicare's HIV Caseload in the Era of Suppressive Therapy Am J Public Health, June 1, 2007; 97(6): 1053 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Parsons, E. Rosof, and B. Mustanski Patient-related Factors Predicting HIV Medication Adherence among Men and Women with Alcohol Problems J Health Psychol, March 1, 2007; 12(2): 357 - 370. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Horberg, L. B. Hurley, D. B. Klein, S. E. Follansbee, C. Quesenberry, J. A. Flamm, G. M. Green, and T. Luu Surgical Outcomes in Human Immunodeficiency Virus-Infected Patients in the Era of Highly Active Antiretroviral Therapy Arch Surg, December 1, 2006; 141(12): 1238 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Bini, J. Park, and F. Francois Use of Flexible Sigmoidoscopy to Screen for Colorectal Cancer in HIV-Infected Patients 50 Years of Age and Older. Arch Intern Med, August 14, 2006; 166(15): 1626 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. R. Blanco, I. S. Garcia, J. G. Cerezo, J. M. P. S. de Rivera, P. M. Anaya, P. G. Raya, J. G. Garcia, J. R. A. Lopez, F. J. B. Hernandez, and J. J. V. Rodriguez Endothelial function in HIV-infected patients with low or mild cardiovascular risk J. Antimicrob. Chemother., July 1, 2006; 58(1): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gu, B. Allard, J. M. de Muys, J. Lippens, R. F. Rando, N. Nguyen-Ba, C. Ren, P. McKenna, D. L. Taylor, and R. C. Bethell In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection Antimicrob. Agents Chemother., February 1, 2006; 50(2): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Khouli, A. Afrasiabi, M. Shibli, R. Hajal, C. R. Barrett, and P. Homel Outcome of Critically Ill Human Immunodeficiency Virus-Infected Patients in the Era of Highly Active Antiretroviral Therapy J Intensive Care Med, December 1, 2005; 20(6): 279 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Vlahov, N. Galai, M. Safaeian, S. Galea, G. D. Kirk, G. M. Lucas, and T. R. Sterling Effectiveness of Highly Active Antiretroviral Therapy among Injection Drug Users with Late-Stage Human Immunodeficiency Virus Infection Am. J. Epidemiol., June 1, 2005; 161(11): 999 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. R. Kitchen, S. Philpott, H. Burger, B. Weiser, K. Anastos, and M. A. Suchard Evolution of Human Immunodeficiency Virus Type 1 Coreceptor Usage during Antiretroviral Therapy: a Bayesian Approach J. Virol., October 15, 2004; 78(20): 11296 - 11302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Springer and A. Weinberg Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity J. Antimicrob. Chemother., September 1, 2004; 54(3): 582 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Eggers and P. L. Kimmel Is There an Epidemic of HIV Infection in the US ESRD Program? J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2477 - 2485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Narasimhan, A. J. Posner, V. A. DePalo, P. H. Mayo, and M. J. Rosen Intensive Care in Patients With HIV Infection in the Era of Highly Active Antiretroviral Therapy Chest, May 1, 2004; 125(5): 1800 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Furfine, C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir Antimicrob. Agents Chemother., March 1, 2004; 48(3): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Koh, H. Nakata, K. Maeda, H. Ogata, G. Bilcer, T. Devasamudram, J. F. Kincaid, P. Boross, Y.-F. Wang, Y. Tie, et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3123 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Roland, B. Lo, J. Braff, and P. G. Stock Key Clinical, Ethical, and Policy Issues in the Evaluation of the Safety and Effectiveness of Solid Organ Transplantation in HIV-Infected Patients Arch Intern Med, August 11, 2003; 163(15): 1773 - 1778. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.-J. Stellbrink, J.-F. Delfraissy, J. Lange, et al. Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia N. Engl. J. Med., May 29, 2003; 348(22): 2186 - 2195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Holzl, M. Stocher, V. Leb, H. Stekel, and J. Berg Entirely Automated Quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Plasma by Using the Ultrasensitive COBAS AMPLICOR HIV-1 Monitor Test and RNA Purification on the MagNA Pure LC Instrument J. Clin. Microbiol., March 1, 2003; 41(3): 1248 - 1251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Trevejo, J. G. Courtney, M. Starr, and D. J. Vugia Epidemiology of Salmonellosis in California, 1990-1999: Morbidity, Mortality, and Hospitalization Costs Am. J. Epidemiol., January 1, 2003; 157(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Little, S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV N. Engl. J. Med., August 8, 2002; 347(6): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Beadle, C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2381 - 2386. [Abstract] [Full Text] [PDF]
|
|
